BLRX 3 SEC Filing Analysis

Latest settled — T+20d

BLRX ▲ +16.89% at T+20d

NEUTRAL call ✓ call won +16.89% · α vs SPY +4.29% · entry $2.25 → $2.63

Next anchor: T+60d in 14d

Last close $3.25 (close Jun 8) · +44.44% from $2.25 entry

Entry anchored
Mar 27, 01:27 PM ET
via Databento tick

T+1d

+2.22%

call +2.22% · α -0.67%

$2.30

settled 2mo ago

T+5d

+0.89%

call +0.89% · α -3.41%

$2.27

settled 2mo ago

T+20d

+16.89%

call +16.89% · α +4.29%

$2.63

settled 6w ago

T+60d

—

call — · α —

—

in 14d

Price Chart

Loading chart...

Executive Summary

Philip A. Serlin, CEO of BioLineRx Ltd., filed a Form 3 disclosing his beneficial ownership of employee stock options totaling 14,719,200 ordinary shares. All options were previously granted under the company's incentive plan, with most fully vested as of the filing date.

Actionable Insight

No immediate trading signal; this is a standard initial ownership disclosure. Monitor for actual option exercises or future insider transactions, which could signal confidence or liquidity needs.

Key Facts

Philip A. Serlin, CEO of BioLineRx Ltd., filed initial statement of beneficial ownership on Form 3
Reporting date for ownership is March 18, 2026
Total reported options: 14,719,200 ordinary shares across seven grants
All options are under the 2003 Amended and Restated Share Incentive Plan
Options have exercise prices ranging from $0.045 to $0.287 per share
Most options are fully vested; 1,404,600 options from the September 6, 2023 grant remain unvested and will vest in five equal quarterly installments
Shares are held via a trustee to qualify for tax benefits under Israeli Section 102

Financial Impact

Potential future dilution of up to 14,719,200 shares if all options are exercised, though no immediate financial impact as this is a routine insider ownership filing

dilutioninsider ownership

Risk Factors

Potential share dilution if large number of options are exercised
Concentration of insider ownership could affect corporate governance dynamics

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

Document	Accession Number
3 Filing (Primary)	0001178913-26-001790
Document: 0001178913-26-001790-index.html	0001178913-26-001790
Document: 0001178913-26-001790.txt	0001178913-26-001790

5 reports for BLRX

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+5▲ +22.92%May 19, 2026

Filters

Reports for BLRX — sortable, filterable
	Type				Now
May 27, 2026 13d ago	6-K MIXED ★ 5/10	$3.37 $3.28	▼ −2.67%	▼ −3.14%	$3.25 (−3.56%)
May 22, 2026 18d ago	6-K BULLISH ★ 6/10	$3.06 $3.48	▲ +13.73%	▲ +12.07%	$3.25 (+6.21%)
May 19, 2026 21d ago	6-K BULLISH ★ 5/10	$2.63 $3.23	▲ +22.92%	▲ +20.67%	$3.25 (+23.57%)
Mar 27, 2026 10w ago	3 NEUTRAL ★ 3/10	$2.25 $2.27	▲ +0.89%	▼ −3.41%	$3.25 (+44.44%)
Mar 26, 2026 10w ago	6-K BULLISH ★ 7/10	$2.33 $2.21	▼ −5.15%	▼ −6.78%	$3.25 (+39.48%)

US Market Status

Market Closed — Opens in 6h 59m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access